Gainers

• Pomdoctor (NASDAQ:POM) shares rose 30.4% to $0.39 during Tuesday's pre-market session. The market value of their outstanding shares is at $36.0 million.
• Omnicell (NASDAQ:OMCL) stock moved upwards by 23.3% to $46.4. The market value of their outstanding shares is at $1.7 billion. As per the press release, Q1 earnings came out today.
• Axogen (NASDAQ:AXGN) shares rose 12.97% to $44.5. The company's market cap stands at $1.9 billion. As per the news, the Q1 earnings report came out today.
• SenesTech (NASDAQ:SNES) stock moved upwards by 12.43% to $1.66. The company's market cap stands at $7.8 million.
• Calidi Biotherapeutics (AMEX:CLDI) stock increased by 11.45% to $0.26. The company's market cap stands at $2.2 million.
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock rose 9.93% to $47.94. The market value of their outstanding shares is at $3.3 billion. As per the press release, Q1 earnings came out today.

Losers

• Soligenix (NASDAQ:SNGX) stock decreased by 51.7% to $0.68 during Tuesday's pre-market session. The market value of their outstanding shares is at $14.2 million.
• Erasca (NASDAQ:ERAS) stock fell 43.29% to $10.86. The company's market cap stands at $5.9 billion.
• iTonic Holdings (NASDAQ:ITOC) stock fell 13.34% to $0.35. The company's market cap stands at $6.9 million.
• HCW Biologics (NASDAQ:HCWB) shares decreased by 12.62% to $0.38. The market value of their outstanding shares is at $2.9 million.
• SciSparc (NASDAQ:SPRC) stock decreased by 11.23% to $7.75. The company's market cap stands at $4.9 million.
• Aditxt (NASDAQ:ADTX) shares declined by 8.84% to $0.23. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.